Nomura Holdings
IMVT icon

Nomura Holdings’s Immunovant IMVT Stock Holding History

Nomura Holdings’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
+29,900
New +$911K ﹤0.01% 1314
2025
Q4 		– Sell
-30,000
Closed -$484K – 2022
2025
Q3 		$484K Buy
+30,000
New +$486K ﹤0.01% 1608
2024
Q2 		– Sell
-50,000
Closed -$1.62M – 1875
2024
Q1 		$1.62M Buy
+50,000
New +$1.82M ﹤0.01% 956

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nomura Holdings's IMVT Position: Q2 2026 in Review

Nomura Holdings sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 16,011 shares — an estimated $488K sold.

Nomura Holdings first reported a position in IMVT in Q1 2024 and held it in 3 quarters. The position peaked at $831K in Q1 2024. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Nomura Holdings reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
  • Nomura Holdings sold 16,011 Immunovant shares in Q2 2026, an estimated $488K.
  • Nomura Holdings first reported a position in Immunovant in Q1 2024 and held it in 3 quarters.
  • Nomura Holdings's Immunovant position peaked at $831K in Q1 2024.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.